Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc.

COLLNYSE / NASDAQHealthcareSmall cap

$24.72-$0.49 (-1.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.1B
P/E
16.9x
EV / EBITDA
4.1x
Revenue
$780.6M
Net margin
8.1%
ROCE
14.7%

-43.8% over the last year

Collegium Pharmaceutical, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+6.4%
3M
-10.2%
6M
-27.8%
1Y
-43.8%
5Y
+31.1%

52-week range

Day change -$0.49 (-1.9%) from $25 to $25 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in COLL, bought on each weekday since 2021.

News & filings

What Collegium Pharmaceutical filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthEV / EBITDA of 4.1 against a peer median of 15.7.

Concerns (1)

  • The P/E of 16.9 is 56% above the peer median of 10.8.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

Read moreShow less

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Sector
Healthcare
Shares outstanding
31.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.1B
P/E
16.9x
P/B
3.5x
EV / EBITDA
4.1x
EV / Sales
2.1x
P/S
1.4x
52-week high
$49.84
52-week low
$21.53

Profitability

Operating margin
22.9%
Net margin
8.1%
EBITDA margin
51.4%
ROE
20.8%
ROCE
14.7%
ROA
3.8%
Asset turnover
0.47

Growth

Revenue
$780.6M
Revenue growth, 1Y
23.6%
Revenue CAGR, 3Y
18.9%
Net profit growth, 1Y
-9.1%
Free cash flow
$327.6M

Solvency

Current ratio
1.57
Debt / Equity
2.70
Debt / Assets
0.49
CFO / Net profit
5.24
Cash / Market cap
21.8%

Where the revenue went

Of every $100 of FY2025 revenue, $8 was left as net income.

Collegium Pharmaceutical, Inc. income statement flow, FY2025
Collegium Pharmaceutical, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$317.3M
RevenueGross profit$463.3M
Gross profitSelling, general and administrative$284.8M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$178.4M
Operating incomePretax income$92.6M
Operating incomeInterest and other expense$85.8M
Pretax incomeTax and other$29.8M
Pretax incomeNet income$62.9M

Revenue and net profit

Revenue grew 23.6% in FY2025; net profit is the dashed line.

Collegium Pharmaceutical, Inc. revenue and net profit by fiscal year
Collegium Pharmaceutical, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$463.9M-$25.0M
FY2023$566.8M$48.2M
FY2024$631.4M$69.2M
FY2025$780.6M$62.9M

Cash flows

FY2025: $329.3M from operations, $327.6M free after investment (dashed).

Collegium Pharmaceutical, Inc. operating and free cash flow by fiscal year
Collegium Pharmaceutical, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$124.2M$122.6M
FY2023$274.7M$274.3M
FY2024$205.0M$203.3M
FY2025$329.3M$327.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$780.6M+23.6%1Y
EBITDA
$401.0M+17.4%1Y
Net profit
$62.9M-9.1%1Y
Cash from operations
$329.3M+60.7%1Y
Free cash flow
$327.6M+61.1%1Y
Revenue CAGR, 3Y
18.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$780.6M$401.0M$62.9M$327.6M20.8%+23.6%-9.1%

Monthly returns

Month-by-month returns of COLL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.7B
Liabilities$1.4B
Equity$301.7M
Paid-in capital$625.0M
Retained earnings-$101.1M
Treasury stock$222.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; COLL highlighted.

P/E against peers

COLL trades at 16.9x earnings against a peer median of 10.8x (a 56% premium).

  1. Collegium Pharmaceutical, Inc. (this company)16.9x

Not shown (no positive earnings and no EV / Sales): Savara Inc., Omada Health, Inc., Azenta, Inc., QuidelOrtho Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Collegium Pharmaceutical, Inc.COLLthis companyP/E ↑ premium$1.1B16.9x3.5x20.8%4.1x
MannKind CorporationMNKD$1.1B185.5x-21.3x-11.5%26.8x
Savara Inc.SVRA$1.1B-9.1x5.3x-58.5%-8.8x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Xeris Biopharma Holdings, Inc.XERS$1.1B1916.5x77.6x4.0%28.6x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
Azenta, Inc.AZTA$1.1B-18.9x0.6x-3.2%20.8x
The Pennant Group, Inc.PNTG$1.0B35.4x3.1x8.9%24.4x
QuidelOrtho CorporationQDEL$1.0B-0.9x0.5x-58.9%-7.7x
Peer median—10.8x2.1x-4.4%15.7x

Year-to-date ROI

COLL since 1 January, against earlier years.

Historical volatility

COLL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Collegium Pharmaceutical, Inc. operating margin by fiscal year
Collegium Pharmaceutical, Inc. operating margin by fiscal year
DateOperating margin
FY20227.2%
FY202329.5%
FY202426.4%
FY202522.9%
LineFY2025
Cost of revenueCost Of Revenue$317.3M
Gross profitGross Profit$463.3M
Operating expensesOperating Expense$284.8M
Research and developmentResearch And Development—
Selling, general and administrativeSelling General And Administration$284.8M
Total expensesTotal Expenses$602.1M
Pretax incomePretax Income$92.6M

Learn while you research

Academy chapters picked for Collegium Pharmaceutical, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing24% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Leverage RatiosDebt/Equity of 2.70 is elevated, understand what that means for solvency.6 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →